Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
Sicilian legacy meats its match: Why this rising star on KC’s food scene was DiCapo’s pick to take over family pizzeria after nearly 100-year run
As a teenager working in downtown Kansas City in the 1990s, Theresa Santos found herself spending her breaks and spare time at the Italian Gardens restaurant on 12th and Baltimore, she recalled. Growing up in New York City and infatuated with Italian culture and food, Santos quickly became friends with the staff — then the…
You shouldn’t have to drive through hell to find a car, founder says; Startup brings concierge service to online auto customers
Not all car buyers want to be in the driver’s seat — especially when attempting to navigate a disconnected roadmap of dealer-focused online marketplaces, said Eric Westphal. “Years ago, when I was looking for a car, I knew what I wanted and I couldn’t find it locally,” said Westphal, describing the inspiration behind Overland Park-based…
‘Perfect for new mRNA vaccines’: Olathe startup targets biotech toward precision delivery
A sudden, then lingering, global pandemic put a spotlight on vaccine technology — with an Olathe startup now positioning itself at the leading edge of both pharmaceutical and vaccine applications for humans and their four-legged counterparts. “We manufacture and develop peptide delivery systems to help deliver drugs and vaccines safer and more effectively,” said Steve…
Hy-Vee plans summit, pitch competition with $45K+ in investments for minority-, women-owned businesses
A Midwest supermarket chain announced this week a new event to help showcase its commitment to advancing minority- and women-owned companies at the home of the Kansas City Chiefs. The Hy-Vee OpportUNITY Inclusive Business Summit is set for Sept. 27 at GEHA Field at Arrowhead Stadium, courtesy of the Chiefs, and is expected to feature…